Related Experiment Videos
[Abciximab: a new antiplatelet agent for use in coronary angioplasty]
M J van den Brand1, M L Simoons
1Academisch Ziekenhuis Rotterdam-Dijkzigt, Thoraxcentrum, GD Rotterdam.
Insights
Abciximab significantly reduces thrombotic complications during percutaneous coronary interventions (PTCA). This glycoprotein IIb-IIIa inhibitor improves outcomes by lowering mortality, myocardial infarction, and urgent interventions, making PTCA safer.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Percutaneous coronary intervention (PTCA) is a standard treatment for symptomatic coronary artery disease.
- Despite advancements, PTCA carries a ~10% risk of thrombotic complications.
- Novel antithrombotic and antiplatelet agents are crucial for improving PTCA safety.
Purpose of the Study:
- To evaluate the efficacy of abciximab, a glycoprotein IIb-IIIa receptor blocker, in reducing thrombotic complications during PTCA.
- To assess the impact of abciximab on major adverse cardiac events and bleeding complications in patients undergoing PTCA.
Main Methods:
- Three large randomized trials were conducted involving patients with stable, unstable, or refractory unstable angina pectoris.
- Abciximab was administered before, during, and after angioplasty procedures.
- Primary endpoint: mortality, myocardial infarction, or urgent intervention at 30 days. Bleeding events were also meticulously recorded.
Main Results:
- Abciximab demonstrated a 35% to 56% relative reduction in the primary combined endpoint across the three trials.
- Severe bleeding rates decreased significantly with optimized heparin dosing and sheath removal protocols, from 14.0% to 3.8% and 2.0% in subsequent trials.
- Placebo groups showed severe bleeding rates of 6.6%, 1.9%, and 3.1%.
Conclusions:
- Abciximab substantially reduces thrombotic complications associated with PTCA.
- The significant reduction in adverse events and manageable bleeding profile supports the broader use of abciximab in angioplasty procedures.
- This agent enhances procedural safety and improves patient outcomes in coronary interventions.
Abstract:
Angioplasty of coronary arteries (PTCA) is an accepted treatment modality for patients with symptomatic coronary artery disease. Despite technological improvements it is still plagued by (mainly thrombotic) complications in around 10% of all patients. A number of new antithrombotic and antiplatelet agents have been tried in the setting of angioplasty. The monoclonal glycoprotein IIb-IIIa receptor blocker abciximab appears to control the thrombotic process most effectively before, during and after the procedure. Three large randomized trials with abciximab in patients with stable, unstable or refractory unstable angina pectoris were conducted. All three showed a relative reduction by 35% to 56% in the primary combined endpoint, consisting of mortality, myocardial infarction or urgent intervention, at 30 days. Severe bleeding, which affected 14.0% of patients on abciximab in the first trial, was reduced, after adjusting heparin dosing and issuing sheath removal guidelines, to 3.8% in the second and 2.0% in the final study. In the placebo groups the percentages of severe bleeding were 6.6, 1.9, and 3.1, respectively. Abciximab appears to reduce the thrombotic complications of PTCA substantially. The extent of this reduction and the severity of complications prevented justifies its more general use during angioplasty.